Conduit Pharmaceuticals Inc. (CDT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
4851 TAMIAMI TRAIL NORTH NAPLES, FL 34103 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 4,228 | 346 | 49 | |||
| Cash and cash equivalents | 4,228 | 346 | 49 | |||
| Receivables | ||||||
| Prepaid expense | 1,505 | 301 | 56 | |||
| Other undisclosed current assets | ||||||
| Total current assets: | 5,733 | 647 | 104 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | ||||||
| Property, plant and equipment | ||||||
| Asset, held-in-trust | 136,871 | |||||
| Other undisclosed noncurrent assets | 1,491 | 109 | ||||
| Total noncurrent assets: | 1,491 | 136,871 | 109 | |||
| TOTAL ASSETS: | 7,224 | 137,518 | 213 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 616 | 43 | ||||
| Accounts payable | 215 | |||||
| Accrued liabilities | 401 | 43 | ||||
| Debt | 185 | 177 | ||||
| Deferred compensation liability | ||||||
| Other undisclosed current liabilities | 1,000 | 375 | 15 | |||
| Total current liabilities: | 1,801 | 418 | 193 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 142 | |||||
| Operating lease, liability | ||||||
| Derivative instruments and hedges, liabilities | 142 | |||||
| Other undisclosed noncurrent liabilities | 5,738 | 4,629 | ||||
| Total noncurrent liabilities: | 5,880 | 4,629 | ||||
| Total liabilities: | 7,681 | 5,047 | 193 | |||
| Temporary equity, carrying amount | 136,771 | |||||
| Equity | ||||||
| Equity, attributable to parent, including: | (457) | (4,300) | 21 | |||
| Common stock | 7 | |||||
| Additional paid in capital | 10,424 | 25 | ||||
| Accumulated other comprehensive income | 411 | |||||
| Accumulated deficit | (11,299) | (4,300) | (4) | |||
| Other undisclosed equity, attributable to parent | 0 | 0 | ||||
| Total equity: | (457) | (4,300) | 21 | |||
| TOTAL LIABILITIES AND EQUITY: | 7,224 | 137,518 | 213 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Other Income) | 115 | ||||
| Gross profit: | 115 | ||||
| Operating expenses | (5,262) | (1,093) | |||
| Other undisclosed operating loss | (115) | (110) | |||
| Operating loss: | (5,262) | (1,203) | |||
| Nonoperating income (expense) | 4,727 | 1,976 | |||
| Investment income, nonoperating | 15 | 1,976 | |||
| Other nonoperating income (expense) | 4,923 | ||||
| Interest and debt expense | (211) | (100) | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (746) | 674 | |||
| Other undisclosed income from continuing operations before income taxes | 100 | ||||
| Income (loss) from continuing operations before income taxes: | (746) | 774 | |||
| Income tax expense | (375) | ||||
| Net income (loss): | (746) | 399 | |||
| Other undisclosed net income attributable to parent | 211 | ||||
| Net income (loss) attributable to parent: | (535) | 399 | |||
| Other undisclosed net loss available to common stockholders, basic | |||||
| Net income (loss) available to common stockholders, basic: | (535) | 399 | |||
| Other undisclosed net loss available to common stockholders, diluted | (5,521) | ||||
| Net income (loss) available to common stockholders, diluted: | (6,056) | 399 | |||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (746) | 399 | |||
| Comprehensive income (loss): | (746) | 399 | |||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (53) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (799) | 399 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.